BioCatalystWatch
ATHEWorkspace / ATHE / OverviewCompany library
ALTERITY THERAPEUTICS LTD logo

ALTERITY THERAPEUTICS LTD

ALTERITY THERAPEUTICS LTD (ATHE)

Price
Market cap
Next catalystExpected 2026ATH434 · Phase 2 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

ATH434

Small molecule

α-Synuclein × Toxic Iron

PreINDP1P2P3FilingApproved
ATH434

Small molecule

α-Synuclein × Toxic Iron

ATH434

Small molecule

α-Synuclein × Toxic Iron

PBT2

PreINDP1P2P3FilingApproved

Partner / License out

PBT2

PreINDP1P2P3FilingApproved

Financial position

Cash and cash equivalents

Source and basis

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ATHE PR & News

PR & News

ATHE SEC archive